Institute for Brain Sciences Research, School of Life Sciences, Henan University, Kaifeng, 475004, People's Republic of China.
Naunyn Schmiedebergs Arch Pharmacol. 2023 Sep;396(9):2039-2055. doi: 10.1007/s00210-023-02430-8. Epub 2023 Mar 14.
Analysis of the commonness of several prescriptions of traditional Chinese medicine (TCM) in the treatment of lung adenocarcinoma (LUAD) based on bioinformatics. Searched the TCM prescriptions for the treatment of LUAD in the literature published in the database, searched ingredients in the TCM through TCMSP and Swiss target prediction databases (OB ≥ 30%, DL > 0.18, Caco-2 > 0), and predicted the potential targets. GEO database retrieved LUAD gene chip data and screened (P < 0.05, | log2 (fold change) |> 1). The biological function, hub gene selection and survival period, immune infiltration, methylation, copy number variations (CNVs), and single-nucleotide variants (SNV) of hub genes were analyzed by DAVID, STRING, Kaplan-Meier plotter database, Cytoscape software, GSCALite database, and TIMER2.0. In this study, 5 TCM prescriptions were analyzed, and a total of 173 ingredients were obtained through database search, including 35 coincidence ingredients, a total of 603 potential targets, 621 LUAD-related genes, 16 up-regulated genes, and 31 down-regulated genes. A total of 61 terms of biological process (BP), 14 terms of cellular component (CC), and 14 terms of molecular function (MF) were obtained. Twenty core genes were obtained, including 15 genes with different survival periods, which were closely related to immune cells (B cell, CD8 + T cell, CD4 + T cell, macrophage, neutrophil, and dendritic cells). The low expression of ADRB2 and MAOA and the high expression of AUARK, CDK1, KIF11, MIF, TOP2A, and TTK were associated with the survival rate of LUAD patients (P < 0.05). Baicalein, Arachidonate, Hederagenin, and hub genes may become potential drugs and potential targets for LUAD treatment. Evaluated the efficacy of TCM in the treatment of LUAD from macro to micro, mined the hub genes, and predicted the mechanism of action, so as to lay the foundation for the development of new drugs of TCM, prescription optimization, or disease control.
基于生物信息学分析中医药治疗肺腺癌（LUAD）的常用方剂。在数据库中检索发表的中医药治疗 LUAD 的方剂文献，通过 TCMSP 和 Swiss target prediction 数据库检索中药成分（OB≥30%，DL>0.18，Caco-2>0），并预测潜在靶点。从 GEO 数据库中检索 LUAD 基因芯片数据，筛选（P<0.05，|log2（fold change）|>1）。通过 DAVID、STRING、Kaplan-Meier plotter 数据库、Cytoscape 软件、GSCALite 数据库和 TIMER2.0 分析关键基因的生物学功能、枢纽基因选择和生存期、免疫浸润、甲基化、拷贝数变异（CNVs）和单核苷酸变异（SNV）。在这项研究中，分析了 5 种中药方剂，通过数据库检索共获得 173 种成分，其中有 35 种重合成分，共 603 个潜在靶点，621 个 LUAD 相关基因，16 个上调基因，31 个下调基因。获得 61 个生物学过程（BP）术语、14 个细胞成分（CC）术语和 14 个分子功能（MF）术语。获得 20 个核心基因，其中有 15 个生存周期不同的基因，与免疫细胞（B 细胞、CD8+T 细胞、CD4+T 细胞、巨噬细胞、中性粒细胞和树突状细胞）密切相关。ADRB2 和 MAOA 表达降低，AUARK、CDK1、KIF11、MIF、TOP2A 和 TTK 表达升高与 LUAD 患者的生存率相关（P<0.05）。白杨素、花生四烯酸、黄岑苷和枢纽基因可能成为 LUAD 治疗的潜在药物和潜在靶点。从宏观到微观评估中医药治疗 LUAD 的疗效，挖掘枢纽基因，预测作用机制，为开发中药新药、处方优化或疾病控制奠定基础。
